• ATP-competitive, reversible inhibitor of AURKA and AURKB
    • Currently no active clinical trials in the United States
    • Recommended dose: 80 mg/kg PO for 5 days of the 21-day cycle; 50 mg/kg for 10 days of the 21-day cycle
    • Half-life: 19 hours
    • Common side effects: Diarrhea, nausea/vomiting, anorexia, fatigue, febrile neutropenia
    (Jones et al., 2008; Schöffski et al., 2011)
    Other topics in Targeted and Immunotherapy Agents